AERIE PHARMACEUTICALS INC (AERI) Forecast, Price Target & Analyst Ratings
NASDAQ:AERI • US00771V1089
15.25 USD
+0.01 (+0.07%)
At close: Nov 18, 2022
15.25 USD
0 (0%)
After Hours: 11/18/2022, 8:21:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AERIE PHARMACEUTICALS INC (AERI).
Forecast Snapshot
Consensus Price Target
$15.63
+ 2.48% Upside
Next Earnings Forecast
Release DateFeb 22, 2023
PeriodQ4 / 2022
EPS Estimate-$0.44
Revenue Estimate39.129M
ChartMill Buy Consensus
71.43%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.63
Upside
+ 2.48%
From current price of $15.25 to mean target of $15.63, Based on 14 analyst forecasts
Low
$6.06
Median
$15.56
High
$26.25
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for AERI. The average price target is 15.63 USD. This implies a price increase of 2.48% is expected in the next year compared to the current price of 15.25.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
71.43%
AERI was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about AERI.
In the previous month the buy percentage consensus was at a similar level.
AERI was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-08-29 | Citigroup | Downgrade | Buy -> Neutral |
| 2022-08-24 | Truist Securities | Downgrade | Buy -> Hold |
| 2022-08-24 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-08-23 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-08-23 | Needham | Downgrade | Buy -> Hold |
| 2022-08-23 | Stifel | Downgrade | Buy -> Hold |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-25 | Needham | Maintains | Buy |
| 2021-11-05 | Needham | Maintains | Buy |
| 2021-08-05 | Needham | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateFeb 22, 2023
PeriodQ4 / 2022
EPS Estimate-$0.44
Revenue Estimate39.129M
Revenue Q2Q-65.88%
EPS Q2Q-140.25%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
AERI is expected to report earnings on 2/22/2023. The consensus EPS estimate for the next earnings is -0.44 USD and the consensus revenue estimate is 39.13M USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 69.89M 189.04% | 83.14M 18.96% | 194.134M 133.50% | 140.26M -27.75% | 183.69M 30.96% | 231.52M 26.04% | 275.5M 19.00% | 304.95M 10.69% | |
| EBITDA YoY % growth | -182.35M 12.04% | -149.32M 18.11% | -39.955M 73.24% | -76.355M -91.10% | -26.553M 65.22% | 8.587M 132.34% | 2.825M -67.10% | 948.109K -66.44% | |
| EBIT YoY % growth | -187.49M 10.61% | -155.69M 16.96% | -46.354M 70.23% | -83.293M -79.69% | -44.865M 46.14% | 153.683K 100.34% | 40.836K -73.43% | 11.068K -72.90% | |
| Operating Margin | -268.26% | -187.26% | -23.88% | -59.38% | -24.42% | 0.07% | 0.01% | 0.00% | |
| EPS YoY % growth | -3.40 26.41% | -3.10 8.82% | -1.02 67.10% | -1.89 -85.63% | -1.03 45.60% | -0.06 94.06% | -0.10 -66.50% | -0.17 -69.83% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.44 -140.25% | -0.33 50.55% | -0.29 10.75% | -0.20 24.44% | -0.10 76.75% |
| Revenue Q2Q % growth | 39.129M -65.88% | 39.678M 32.99% | 42.738M 28.30% | 47.736M 32.13% | 55.123M 40.88% |
| EBITDA Q2Q % growth | -16.472M -128.33% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -18.121M -135.02% | -13.389M 60.20% | -11.839M 34.72% | -7.87M 70.49% | -2.657M 85.34% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.72%
EPS Next 5 Year
12.85%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
26.90%
Revenue Next 5 Year
21.90%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
27.69%
EBIT Next 5 Year
14.97%
AERIE PHARMACEUTICALS INC / AERI Forecast FAQ
What is the price target for AERI stock?
14 analysts have analysed AERI and the average price target is 15.63 USD. This implies a price increase of 2.48% is expected in the next year compared to the current price of 15.25.
When does AERIE PHARMACEUTICALS INC (AERI) report earnings?
AERIE PHARMACEUTICALS INC (AERI) will report earnings on 2023-02-22.
Can you provide the consensus estimates for AERIE PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of AERIE PHARMACEUTICALS INC (AERI) is -0.44 USD and the consensus revenue estimate is 39.13M USD.
How many analysts cover AERIE PHARMACEUTICALS INC (AERI) stock?
The number of analysts covering AERIE PHARMACEUTICALS INC (AERI) is 14.